In times of extreme stress, people fall back on black humor, which explains the joke making the rounds of health care buysiders trying to cope with the relentless selling of biotech and drug stocks.

“Are you hearing anything about a big fund liquidating? This market feels like a big fund is liquidating.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You try to be greedy when others are afraid, and try to be afraid when others are greedy…Warren Buffett

  • small cap Biotechs have been shorted mercilessly and subsequently subjected to all kinds of hit pieces.

    Look no further than JP Morgan’s dishonest and lazy hit job on SGMO today.

    Mr. Feuerstein should know a thing or two about shorting a company and then writing misleading hit pieces.

    • That JPM piece on SGMO was awful. Not only was it factually inaccurate, but the analyst apparently flubbed the numbers horribly. Either sloppy, incredibly stupid, or purposefully malignant, hard to decide which. I have no position in SGMO but my sympathies go out to the shareholders on this one.

    • Any different than the mob?

      Tom, wait a minute. I’m talking about a cop — that’s mixed up in drugs. I’m talking about ah
      – ah – a dishonest cop — a crooked cop who got mixed up in the rackets and got what was
      coming to him. That’s a terrific story. And we have newspaper people on the payroll, don’t
      we, Tom?
      [Hagen nods in the affirmative]
      And they might like a story like that.

      They might, they just might…

  • Do you think owning MDGL and VKTX is worth at these prices or expecting more downside – if one dares to own these until 2022-23?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy